Literature DB >> 3257099

Polymorphism and complexity of HLA-DR: evidence for intra-HLA-DR region crossing-over events.

R E Bontrop1, M G Tilanus, M M Mikulski, D G Elferink, A Termijtelen, R R de Vries, J J van Rood, M J Giphart.   

Abstract

HLA-DR molecules were isolated from HLA-DR3, -5, and -w6 positive homozygous B-cell lines by immunoprecipitation with monoclonal antibodies and analyzed by gel electrophoretic techniques. DNA isolated from the same cell lines was digested with the restriction enzyme Taq I and hybridized with a DR beta full-length cDNA probe. We demonstrated that certain DR beta I alleles are found in combination with different DR beta III alleles as defined by Southern blotting, protein chemistry, a functional assay using purified protein derivative-specific T-cell lines, and, in one case, also alloreactive T-cell reagents. Our results indicate that within the family of HLA-DRw52-associated haplotypes DR beta chain genes may have been transferred from one haplotype to another. The implications of these findings are discussed.

Mesh:

Substances:

Year:  1988        PMID: 3257099     DOI: 10.1007/bf00404442

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  21 in total

1.  HLA-DR beta genes vary in number between different DR specificities, whereas the number of DQ beta genes is constant.

Authors:  J Böhme; M Andersson; G Andersson; E Möller; P A Peterson; L Rask
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

2.  DQ alpha and beta RFLP reveals the composition of the DQ molecule recognized by T-cell clones.

Authors:  S Rosenshine; I Cascino; A Zeevi; R J Duquesnoy; M Trucco
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

3.  Histocompatibility 1984.

Authors:  J Bodmer; W Bodmer
Journal:  Immunol Today       Date:  1984-09

4.  Quantitative and qualitative differences in HLA-DR molecules correlated with antigen-presentation capacity.

Authors:  R Bontrop; T Ottenhoff; R Van Miltenburg; D Elferink; R De Vries; M Giphart
Journal:  Eur J Immunol       Date:  1986-02       Impact factor: 5.532

5.  Structural organization of the DR subregion of the human major histocompatibility complex.

Authors:  T Spies; R Sorrentino; J M Boss; K Okada; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

6.  Characterization of an HLA DR beta pseudogene.

Authors:  D Larhammar; B Servenius; L Rask; P A Peterson
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

Review 7.  HLA-linked lymphocyte activating determinants.

Authors:  A Termijtelen; A van Leeuwen; J J van Rood
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

8.  The HLA class II genes and products: the HLA-D region.

Authors:  F H Bach
Journal:  Immunol Today       Date:  1985-03

9.  Human T-cell clones used to define functional epitopes on HLA class II molecules.

Authors:  C M Weyand; J Goronzy; C G Fathman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

10.  Monoclonal antibodies defining serologically distinct HLA-D/DR related Ia-like antigens in man.

Authors:  L M Nadler; P Stashenko; R Hardy; J M Pesando; E J Yunis; S F Schlossman
Journal:  Hum Immunol       Date:  1981-02       Impact factor: 2.850

View more
  3 in total

1.  Bovine MHC class II restriction fragment length polymorphism linked to expressed polymorphism.

Authors:  I Joosten; E J Hensen; M F Sanders; L Andersson
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

2.  The chimpanzee major histocompatibility complex class II DR subregion contains an unexpectedly high number of beta-chain genes.

Authors:  R E Bontrop; L A Broos; K Pham; R M Bakas; N Otting; M Jonker
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

3.  Major histocompatibility complex class II-restricted antigen presentation across a species barrier: conservation of restriction determinants in evolution.

Authors:  R E Bontrop; D G Elferink; N Otting; M Jonker; R R de Vries
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.